[1]王涛,马信龙.骨质疏松发病机制研究进展[J].国际内分泌代谢杂志,2014,(02):99-102.[doi:10.3760/cma.j.issn.1673-4157.2014.02.008]
 Wang Tao,Ma Xinlong..Research progress on pathogenesis of osteoporosis[J].International Journal of Endocrinology and Metabolism,2014,(02):99-102.[doi:10.3760/cma.j.issn.1673-4157.2014.02.008]
点击复制

骨质疏松发病机制研究进展()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年02期
页码:
99-102
栏目:
骨代谢疾病专栏
出版日期:
2014-04-30

文章信息/Info

Title:
Research progress on pathogenesis of osteoporosis
作者:
王涛马信龙
300211 天津医院脊柱外科   
Author(s):
Wang TaoMa Xinlong.
Department of Spine Surgery,Tianjin Hospital,Tianjin 300211,China Corresponding author:Ma Xinlong,Email:maxinlong8686@126.com
关键词:
骨质疏松骨代谢骨硬化蛋白G蛋白耦联受体胶原蛋白基因
Keywords:
OsteoporosisBone metabolismBone sclerosisG protein-coupled proteinCollagen protein gene
DOI:
10.3760/cma.j.issn.1673-4157.2014.02.008
摘要:
骨质疏松是以骨量减少、骨组织微结构破坏进而导致骨脆性和骨折危险性增加为特征的疾病。激素在骨代谢中具有重要作用,但近年来又发现其他危险因素,如骨硬化蛋白、胶原蛋白基因、G蛋白耦联受体、骨形态发生蛋白、胰岛素样生长因子等。探讨危险因素对骨质疏松形成的影响,将为寻找新的治疗靶点提供方向。
Abstract:
Osteoporosis is characterized by decrease of bone mass and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fractures.Hormones play an important role in regulating bone metabolism,however,other risk factors are identified including collagen protein gene,G protein-coupled receptor,bone morphogenetic protein and insulin-like growth factor,etc.Investigating the effects of risk factors on osteoporosis will provide new therapeatic targets.

参考文献/References:

 [1] Arasu A,Cawthon PM,Lui LY,et al. Serum sclerostin and risk of hip fracture in older Caucasian women[J].J Clin Endocrinol Metab,2012,97(6):2027-2032.  
[2] Li C,Ominsky MS,Tan HL,et al. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene[J]. Bone,2011,49(6):1178-1185.  
[3] Wijenayaka AR,Kogawa M,Lim HP,et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway [J].PLoS One,2011,6(10):e25900.  
[4] Bonewald LF. The amazing osteocyte[J]. J Bone Miner Res,2011, 26(2):229-238.  
[5] Genetos DC,Toupadakis CA,Raheja LF,et al. Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts [J]. J Cell Biochem,2010,110(2):457-467.  
[6] Lin C,Jiang X,Dai Z,et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling[J]. J Bone Miner Res,2009,24(10):1651-1661.  
[7] Yu EW,Kumbhani R,Siwila-Sackman E,et al. Acute decline in serum sclerostin in response to PTH infusion in healthy men[J].J Clin Endocrinol Metab,2011,96(11):E1848-E1851.  
[8] Ominsky MS,Vlasseros F,Jolette J,et a1.Two doses of sclerostin antibody in cynomolgus monkeys increased bone formation,bone mineral density,and bone strength[J].J Bone Miner Res,2010,25(5):948-959.  
[9] McDonald MM,Morse A,Mikulec K,et al.Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats[J]. J Orthop Res,2012,30(10):1541-1548.
[10] Luo J,Zhou W,Zhou X,et al. Regulation of bone formation and remodeling by G-protein-coupled receptor 48 [J]. Development,2009,136 (16):2747-2756.
[11] Kajimura D,Hinoi E,Ferron M,et al. Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual[J].J Exp Med,2011,208(4):841-851.
[12] Wang W,Lian N,Ma Y,et al.Chondrocytic Atf4 regulates osteoblast differentiation and function via Ihh[J].Development,2012,139(3):601-611.
[13] Horiguchi M,Koyanagi S,Okamoto A,et al.Stress-regulated transcription factor ATF4 promotes neoplastic transformation by suppressing expression of the INK4a/ARF cell senescence factors [J]. Cancer Res,2012,72(2):395-401.
[14] Huang Z,Ren PG,Ma T,et al.Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability [J]. Cytokine,2010,51(3):305-310.
[15] Chen G,Deng C,Li YP. TGF-β and BMP signaling in osteoblast differentiation and bone formation[J].Int J Biol Sci,2012,8(2):272-288.
[16] Papathanasiou I,Malizos KN,Tsezou A.Bone morphogenetic protein-2-induced Wnt/beta-catenin signaling pathway activation through enhanced low-density-lipoprotein receptor-related protein 5 catabolic activity contributes to hypertrophy in osteoarthritic chondrocytes[J]. Arthritis Res Ther,2012,14(2):R82.
[17] Tang N,Song WX,Luo J,et al. BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling[J].J Cell Mol Med,2009, 13(8B):2448-2464.
[18] Kamiya N,Ye L,Kobayashi T,et al. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway[J]. Development,2008,135(22):3801-3811.
[19] Egermann M,Lill CA,Griesbeck K,et al. Effect of BMP-2 gene transfer on bone healing in sheep[J]. Gene Ther,2006,13(17):1290-1299.
[20] Gruodyte R,Jürim?覿e J,Saar M,et al.The relationships among bone health,insulin-like growth factor-1 and sex hormones in adolescent female athletes[J].J Bone Miner Metab,2010,28(3):306-313.
[21] Lloyd SA,Simske SJ,Bogren LK,et al.Effects of combined insulin-like growth factor 1 and macrophage colony-stimulating factor on the skeletal properties of mice[J]. In Vivo,2011,25(3):297-305.
[22] Breen ME,Laing EM,Hall DB,et al.25-hydroxyvitamin D,insulin-like growth factor-I,and bone mineral accrual during growth[J]. J Clin Endocrinol Metab,2011,96(1):E89-E98.
[23] Lombardi G,Di Somma C,Vuolo L,et al. Role of IGF-I on PTH effects on bone[J].J Endocrinol Invest,2010,33(7 Suppl):22-26.
[24] Chen L,Jiang W,Huang J,et al. Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation[J].J Bone Miner Res,2010,25(11):2447-2459.
[25] Husted LB,Harsl?覬f T,Gonzalez-Bofill N,et al. Haplotypes of promoter and intron 1 polymorphisms in the COLIA1 gene are associated with increased risk of osteoporosis[J].Calcif Tissue Int,2009,84(2):85-96.
[26] González-Bofill N,Husted LB,Harsl?覬f T,et al.Effects of COLI-A1 polymorphisms and haplotypes on perimenopausal bone mass, postmenopausal bone loss and fracture risk[J]. Osteoporos Int,2011,22(4):1145-1156.
[27] Jin H,Evangelou E,Ioannidis JP,et al. Polymorphisms in the 5' flank of COL1A1 gene and osteoporosis:meta-analysis of published studies[J]. Osteoporos Int,2011,22(3):911-921.

相似文献/References:

[1]姜艳,孟迅吾.雷尼酸锶防治骨质疏松的机制和临床研究[J].国际内分泌代谢杂志,2007,(04):247.
[2]郭丽婷,郝帅,高志红.2型糖尿病患者骨代谢生化指标和钙调激素 与骨密度关系的研究[J].国际内分泌代谢杂志,2015,(02):88.[doi:10.3760/cma.j.issn.1673-4157.2015.02.005]
 Guo Liting,Hao Shuai,Gao Zhihong..Research on the relationship between bone mineral density and biochemical index of bone metabolism ,calmodulin hormone in type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(02):88.[doi:10.3760/cma.j.issn.1673-4157.2015.02.005]
[3]尹飞,李菲,李志红.亚临床甲状腺功能异常与骨质疏松[J].国际内分泌代谢杂志,2015,(04):258.[doi:10.3760/cma.j.issn.1673-4157.2015.04.012]
 Yin Fei,Li Fei,Li Zhihong..Subclinical thyroid dysfunction and osteoporosis[J].International Journal of Endocrinology and Metabolism,2015,(02):258.[doi:10.3760/cma.j.issn.1673-4157.2015.04.012]
[4]王育榕,孙嘉.脂肪因子对骨代谢影响的研究进展[J].国际内分泌代谢杂志,2014,(02):95.[doi:10.3760/cma.j.issn.1673-4157.2014.02.007]
 Wang Yurong,Sun Jia..Influence of adipokines on bone metabolism[J].International Journal of Endocrinology and Metabolism,2014,(02):95.[doi:10.3760/cma.j.issn.1673-4157.2014.02.007]
[5]蒋真斌,孙嘉.白细胞介素-17与骨质疏松[J].国际内分泌代谢杂志,2014,(02):103.[doi:10.3760/cma.j.issn.1673-4157.2014.02.009]
 Jiang Zhenbin*,Sun Jia.Interleukin-17 and osteoporosis[J].International Journal of Endocrinology and Metabolism,2014,(02):103.[doi:10.3760/cma.j.issn.1673-4157.2014.02.009]
[6]田甜,沈山梅.肠促胰素与骨质疏松[J].国际内分泌代谢杂志,2016,36(05):320.[doi:10.3760/cma.j.issn.1673-4157.2016.05.09]
 Tian Tian,Shen Shanmei.Incretin and osteoporosis[J].International Journal of Endocrinology and Metabolism,2016,36(02):320.[doi:10.3760/cma.j.issn.1673-4157.2016.05.09]
[7]梁珊珊 刘昊凌 高昕媛 辛玉晶.2型糖尿病合并下肢动脉疾病患者血清 FGF-23与骨钙素的关系研究[J].国际内分泌代谢杂志,2020,40(01):10.[doi:DOI:10.3760/cma.j.issn.1673-4157.2020.01.003]
 Liang Shanshan,Liu Haoling,Cao Xinyuan,et al.Relationship between serum FGF-23 and osteocalcin in patients with type 2 diabetes mellitus complicated with lower extremity arterial disease[J].International Journal of Endocrinology and Metabolism,2020,40(02):10.[doi:DOI:10.3760/cma.j.issn.1673-4157.2020.01.003]

备注/Memo

备注/Memo:
通信作者:马信龙,Email:maxinlong8686@126.com
更新日期/Last Update: 2014-03-20